According to the complaint, the network was processing a huge volume of reimbursement claims for Gilead's HIV pre-exposure prophylaxis (PrEP) medicines Truvada (emtricitabine/tenofovir disoproxil ...

The notice of claim contends Gilead developed two drugs, tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide fumarate (TAF). TDF is “effective in managing HIV/AIDS but can damage ...

Jan 15 (Reuters) - Gilead Sciences (GILD.O), opens new tab and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to ...

Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and Descovy for pre-exposure prophylaxis (PrEP). The government was ...

Gilead Sciences, US Government Settle Patent Case Over HIV Prevention Drugs By Blake Brittain (Reuters) - Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over ...

This case challenges the mandated ... Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi. Read More on GILD: Gilead Sciences NewsMORE Related Stocks Indices ...

The combination of tenofovir, didanosine, and lamivudine is not recommended when considering a new treatment regimen for therapy-naive or treatment-experienced patients with HIV infection.

(Reuters) - Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to a Wednesday filing in Delaware ...